VTYX

Ventyx Biosciences

Fundamental data last updated:March 2, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

Nasdaq

County of HQ

United States

Next Earnings Date

-

Business Summary

Ventyx Biosciences is a biotechnology company focused on developing therapies for immune-mediated and inflammatory diseases. It advances drug candidates through research and clinical development with the goal of bringing new treatments to market.

 


Analyze VTYX on TradingView

VALUATION

P/E

-

Market Cap ($M USD)

$1,002

Forward P/E

-

PEG

-

PRICE TO SALES

-

PRICE TO BOOK

5.2

EV / EBITDA

5-Year Average P/E

Free Cash Flow Yield

DCF Value

Graham Number

Price to FCF

EV to FCF

Earnings Yield

FCF Yield

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$1.49

Next Year EPS Growth Estimate

-$1.63

Next Year Revenue Growth Estimate

-

Return on Equity (ROE)

-55.70%

FREE CASH FLOW

Operating Margin

-

Debt-to-Equity

0.1

Piotroski F-Score

Altman Z-Score

Return on Invested Capital (ROIC)

Current Ratio

Quick Ratio

Net Debt to EBITDA

Interest Coverage

Gross Profit margin

FCF PER SHARE

REVENUE PER SHARE

Analyze VTYX on TradingView

Gainseekers Quantitative Analysis

Summary

Ventyx Biosciences is a Nasdaq-listed biotechnology company with a market capitalization of $1,002 million operating within the Healthcare sector. The company is currently unprofitable, reporting EPS of -$1.49 and a return on equity of -55.70%, with EPS next year estimated at -$1.63. It has a relatively low debt-to-equity ratio of 0.1, institutional ownership of 84.40%, and a consensus rating of 3 with a mean target price of $13.44.

AI Exposure / Tech Reliance

As a biotechnology company, its business is driven primarily by scientific research and drug development rather than artificial intelligence-specific products. Any AI exposure would likely be supportive in research activities rather than a core revenue driver.

The Bull Case

The company maintains a strong balance sheet with a low debt-to-equity ratio of 0.1 and significant institutional ownership at 84.40%, indicating confidence from large investors. Its $1,002 million market cap and consensus target price of $13.44 suggest potential upside if development milestones are achieved.

The Bear Case

The company is currently unprofitable with EPS of -$1.49 and a negative return on equity of -55.70%, with losses expected to continue next year at an estimated -$1.63 EPS. The absence of positive earnings metrics and undefined forward valuation measures increases uncertainty and risk.

Market Sentiment & Smart Money

Short Interest %

6.70%

Analyst Consensus

3

Average Analyst Price Target

$13.44

Institutional Ownership %

84.40%

1-Year Beta

Insider Buying % (6 Mo)

Distance to 52-Week High

Distance to 52-Week Low

EARNINGS SURPRISE %

50-DAY SMA

200-DAY SMA

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.